Alcohol Consumption Emerges as a Key Risk Factor for Buccal Cancer in India
December 24, 2025
Free CME credits
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
Brand Name :
No Data Available.
Synonyms :
lansoprazole
Class :
Proton pump inhibitors
Brand Name :
No Data Available.
Synonyms :
lansoprazole
Class :
Proton pump inhibitors
Administer 15 mg orally every day for a month as active dose Administer 15 mg orally every day as maintenance dose
Take 30 mg orally every day for the duration of eight weeks
when both drugs are combined, there may be a decrease in levels of serum concentration and absorption of erlotinib
it may decrease the serum concentration of bosutinib
may decrease the serum concentration
belumosudil: they may diminish the serum concentration of Inhibitors of the Proton Pump
may decrease the diagnostic effect of each other when combined
it may decrease the absorption of Levoketoconazole
may decrease the serum concentration
they decrease the concentration of active metabolites of infigratinib in the serum
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
it may diminish the therapeutic effect of Immune Checkpoint Inhibitors
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivative
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of bisphosphonate derivatives
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
may diminish the therapeutic effect of immune checkpoint inhibitors
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
Inhibitors of the Proton Pump: they may decrease the therapeutic effect of oral bisphosphonate derivatives
may enhance the concentration of serum when combined with lansoprazole
may enhance the concentration of serum when combined with lansoprazole
When dexrabeprazole and lansoprazole is used together, this leads to reduction in the dexrabeprazole’s metabolism
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
It may enhance the risk of adverse effects when combined with Proton pump inhibitors
When encainide is used together with lansoprazole, this leads to a reduction in the encainide’s metabolism
When bacampicillin is combined with lansoprazole, bacampicillin absorption and blood levels decrease by stomach acid reduction.
when both drugs are combined, there may be an increased risk of hypomagnesemia
the effect of lansoprazole is decreased by lorlatinib, by altering intestinal or hepatic CYP3A4 enzyme metabolism
Proton Pump inhibitors may increase the absorption of amphetamine
l-methylfolate-pyridoxal 5′-phosphate-methylcobalamine
it may decrease the serum concentration of Multivitamins
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
it may decrease the serum concentration of Minerals
may increase the serum concentration of itraconazole
they decrease the efficacy of cysteamine
This could lead to a reduction in concentration serum of mycophenolate
Actions and spectrum:
Actions:
Lansoprazole inhibits H+/K+ ATPase in stomach cells, reducing acid production.
Spectrum:
Lansoprazole treats GERD, H.pylori, ulcers, and Zollinger-Ellison syndrome.
Frequency defined:
1%-10%
Abdominal pain
Constipation
Diarrhea
Nausea
Dizziness
Headache
<1%:
Bradycardia
Chest pain
Pruritis
Decreased libido
Diabetes mellitus
Goiter
Abdominal distension
Black Box Warning
Lansoprazole may cause kidney issues
Contraindication/Caution:
Contraindication:
Hypersensitivity
Concomitant administration with products containing rilpivirine
Cautions:
Clostridium difficile- associated diarrhea
Severe reactions on the skin
Cutaneous lupus erythematosus
Stevens-Johnson syndrome
Toxic epidermal necrolysis
Acute generalized exanthematous pustulosis
Fundic gland polyp
TIN (acute tubulointerstitial nephritis)
Pregnancy consideration: No adverse effects have been reported in animal reproduction studies. It can be recommended for the treatment of GERD in pregnant women.
Lactation: Excretion of lansoprazole in breast milk is not known.
Pregnancy category:
Category A: Satisfactory and well-controlled studies show no risk to the fetus in the first or later trimester.
Category B: There is no evidence of risk to the fetus found in animal reproduction studies and there are not enough studies on pregnant women.
Category C: Adverse effects on the fetus found with evidence in animal reproduction studies and no adequate evidence for an effect in humans, care must be taken for potential risks in pregnant women
Category D: There is adequate data available with sufficient evidence of human fetal risk from various platforms, but despite potential risks may be used only in emergency cases for potential benefits.
Category X: Drugs listed in this category outweigh risks over benefits These category drugs should be prohibited for pregnant women.
Category N: There is no data available for the drug under this category.
Pharmacology:
Lansoprazole is a proton pump inhibitor, used as an antisecretory agent.
Pharmacodynamics:
Lansoprazole reduces gastric acid secretion by inhibiting H+/K+ ATPase in stomach cells, and decreases pepsin secretion, treating hypersecretory conditions like Zollinger-Ellison syndrome.
Pharmacokinetics:
Absorption
Lansoprazole is taken orally and has an oral bioavailability of 80-90%
Distribution
Volume of distribution: 14-18 L/kg.
Drug binding to plasma proteins: 97%.
Metabolism
Lansoprazole is metabolized in the liver by CYP2C19 and CYP3A4.
Elimination and excretion
14-23% of lansoprazole eliminated the body through urine as both unconjugated and conjugated hydroxylated forms.
Half-life
The half-life is 0.9 to 1.5 hour
Administration:
Take Lansoprazole orally before eating.
Don’t chew or crush the tablet/capsule.
Intravenous administration should last over 30 minutes.
Generic Name: lansoprazole
Pronounced: lan-so-pra-zole
Why do we use lansoprazole?
Lansoprazole is a proton pump inhibitor (PPI) used to decrease the amount of acid produced in the stomach. It is commonly prescribed for the treatment of gastroesophageal reflux disease (GERD), where it helps relieve symptoms such as heartburn and acid regurgitation, and aids in the healing of erosive esophagitis caused by stomach acid. Lansoprazole is also used in managing peptic ulcer disease, including both gastric and duodenal ulcers. In cases where Helicobacter pylori infection is present, it is often combined with antibiotics like amoxicillin and clarithromycin to eradicate the infection and promote ulcer healing.
Both our subscription plans include Free CME/CPD AMA PRA Category 1 credits.
On course completion, you will receive a full-sized presentation quality digital certificate.
A dynamic medical simulation platform designed to train healthcare professionals and students to effectively run code situations through an immersive hands-on experience in a live, interactive 3D environment.
When you have your licenses, certificates and CMEs in one place, it's easier to track your career growth. You can easily share these with hospitals as well, using your medtigo app.
